SpineSeal Spine Sealant
Pramand, LLC · Decision date Sep 11, 2026
What did the FDA approve?
The FDA recorded approval of supplement P240027/S007 for SpineSeal™ Spine Sealant, sponsored by Pramand, LLC, on 2026-09-11. The supplement is classified as a real-time process change with the reason Change Design/Components/Specifications/Material. The recorded scope is a decrease in the lower specification limit for product swelling. This action amends the existing PMA rather than constituting a new approval of the whole sealant system.
The device falls under the dural sealant category, product code NQR, with neurology listed as the specialty. The source record does not include the prior specification value, the revised limit, supporting test data, or the supplement documents, so the magnitude and basis of the change remain unknown. No clinical or performance conclusions about the product follow from this record alone.
FDA approval order statement
Approval to decrease the lower specification limit for product swelling.
- Regulatory pathway
- PMA supplement
- Supplement type
- Real-Time Process
- Clinical specialty
- Neurology
- Decision date
- Sep 11, 2026
- FDA change category
- Change Design/Components/Specifications/Material
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- P240027/S007
- Regulatory pathway
- PMA supplement
- Applicant
- Pramand, LLC
- Product code
- NQR
- Decision code
- APPR
- Decision date
- Sep 11, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Sealant, dural.
- Applicant
- Pramand, LLC
- Product code
- NQR
- FDA device class
- 3
For the original device and its historical approval scope, see PMA P240027. Subsequent supplements may change the device or its indications.
FDA decision timeline
P240027 · Original PMA
SpineSeal Spine Sealant
P240027/S007 received
Application receipt date recorded by FDA.
P240027/S007 · FDA decision
Real-Time Process
Timeline entries are records held by MedtechLedger for P240027. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P240027
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
SpineSeal Spine SealantP240027 | Pramand, LLC | PMA approval | Feb 14, 2025 | FDA |
Explore the linked device profile
Other records with product code NQR
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
CraniSeal Dural SealantP220014/S013 | Pramand, LLC | PMA supplement | Oct 1, 2026 | FDA |
CraniSeal Dural SealantP220014 | Pramand, LLC | PMA approval | Jul 6, 2023 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
FDA describes the real-time supplement process as a review route for minor changes to a device, including certain design, software, sterilization or labeling changes.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Pramand, LLC
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 201 Burlington Rd., Suite 210, Bedford, MA, 02420
Sources and methodology
- Original FDA record: P240027/S007
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records
